tradingkey.logo
tradingkey.logo
Search

Pharmaceuticals

LIST1043
2176.539USD
-18.792-0.86%
ETQuotes delayed by 15 min
3.85TMarket Cap
188.86MVolume
2176.539Open
2182.457High
188.86MVolume
78Up
97Down
16Unchanged
3.85TMarket Cap
2176.539Prev. Close
2151.163Low
7.59BTurnover

Pharmaceuticals

2176.539
-18.792-0.86%

Related Stocks

No.
Name
Price
Change
Chg %
Total Score
Time
Volume
Turnover
Market Cap
Shares
Amplitude
Volume Ratio
52wk High
52wk Low
Dividends
Div Yield
5D
10D
20D
60D
120D
250D
Year to Date
Watchlist
NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals Inc
NBY
1.930
+0.340
+21.38%
3.94
574.04K
518.07K
1.82K
941.29
25.78
1.97
99.750
1.110
0.00
0.00
+35.92%
+50.78%
+32.19%
-94.28%
-67.83%
+2.09%
-93.16%
Lexaria Bioscience Corp
Lexaria Bioscience Corp
LEXX
1.010
+0.144
+16.61%
6.34
569.90K
420.43K
608.51K
602.49K
19.62
4.18
1.701
0.460
0.00
0.00
+30.36%
+35.57%
+42.45%
+42.31%
+11.03%
-39.52%
+63.70%
Medicus Pharma Ltd
Medicus Pharma Ltd
MDCX
0.458
+0.038
+9.10%
4.06
516.59K
150.86K
1.37M
3.00M
16.30
0.34
8.940
0.370
0.00
0.00
-7.23%
-8.36%
-66.80%
-71.36%
-81.37%
-86.52%
-70.05%
4
Universe Pharmaceuticals Inc
Universe Pharmaceuticals Inc
UPC
2.915
+0.215
+7.96%
1.78
7.64K
15.71K
17.00K
5.83K
15.16
1.13
11.000
2.000
0.00
0.00
+29.71%
+9.18%
+10.42%
-28.73%
-69.19%
+2.28%
-23.49%
5
Elutia Inc
Elutia Inc
ELUT
1.175
+0.085
+7.80%
6.45
55.50K
49.35K
12.02M
10.23M
10.09
0.64
2.990
0.500
0.00
0.00
+4.91%
+8.80%
-1.26%
+91.37%
+32.17%
-57.58%
+69.63%
6
Scilex Holding Co
Scilex Holding Co
SCLX
7.410
+0.500
+7.24%
5.51
43.49K
142.89K
29.93M
4.04M
14.28
2.20
34.270
3.600
0.00
0.00
+10.27%
-4.02%
-15.12%
-44.12%
-57.85%
-28.84%
-39.26%
7
Tilray Brands Inc
Tilray Brands Inc
TLRY
6.575
+0.435
+7.08%
6.37
4.95M
22.60M
603.55M
91.79M
12.54
1.85
23.200
3.507
0.00
0.00
-5.26%
-2.30%
-9.93%
-30.75%
-61.77%
+0.94%
-27.19%
8
MANE.NB
MANE.NB
MANE
62.700
+3.920
+6.67%
--
709.74K
32.40M
2.20B
35.08M
8.81
1.42
53.630
32.000
0.00
0.00
--
--
--
--
--
--
--
9
Journey Medical Corp
Journey Medical Corp
DERM
4.910
+0.270
+5.82%
7.20
255.87K
845.43K
80.73M
16.44M
12.06
0.38
9.555
4.310
0.00
0.00
-28.11%
-31.04%
-38.93%
-31.04%
-34.71%
-21.31%
-36.32%
10
Abeona Therapeutics Inc
Abeona Therapeutics Inc
ABEO
4.835
+0.255
+5.57%
7.27
540.20K
1.76M
93.39K
19.32K
7.42
0.49
7.540
3.933
0.00
0.00
+9.39%
+6.26%
-2.72%
-7.38%
-12.73%
+3.31%
-8.25%

News

Weight-Loss Drug Giant Eli Lilly Bets Big Again. Spending $7.8 Billion to Acquire Centessa, Is Now a Good Time to Buy Eli Lilly?

TradingKey - On March 31, Eastern Time, Eli Lilly officially announced its acquisition of U.S.-listed Centessa Pharmaceuticals for a total consideration of $7.8 billion, with the transaction expected to close in the third quarter of 2026. Following the news, Eli Lilly shares rose approximately 3% on Tuesday, while Centessa shares surged 45%.

TradingKeyWed, Apr 1
TradingKey - On March 31, Eastern Time, Eli Lilly officially announced its acquisition of U.S.-listed Centessa Pharmaceuticals for a total consideration of $7.8 billion, with the transaction expected to close in the third quarter of 2026. Following the news, Eli Lilly shares rose approximately 3% on Tuesday, while Centessa shares surged 45%.

Today’s Market Recap: Markets Edge Up Amid Iran Conflict and Fed Rate Scrutiny

U.S. indices edged higher as investors weighed optimistic tech developments from Nvidia, Amazon, and Micron against a volatile geopolitical backdrop.

TradingKeyWed, Mar 18
U.S. indices edged higher as investors weighed optimistic tech developments from Nvidia, Amazon, and Micron against a volatile geopolitical backdrop.

Rhythm Pharma's Drug Fails Key Genetic Obesity Trial, Shares Fall

March 16 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.

ReutersTue, Mar 17
March 16 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.

What Are Defensive Stocks? Best Defensive Stocks to Buy in 2026

TradingKey - Defensives run on resilience: predictable demand, strong cash flow, conservative balance sheets, and tame volatility. You can’t just look at a sector name to find them. It requires a systematic examination of cash generation, leverage, dividend sustainability, beta, competitive moats, a

TradingKeyMon, Mar 16
TradingKey - Defensives run on resilience: predictable demand, strong cash flow, conservative balance sheets, and tame volatility. You can’t just look at a sector name to find them. It requires a systematic examination of cash generation, leverage, dividend sustainability, beta, competitive moats, a

Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market

TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.

TradingKeyThu, Mar 12
TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.

Novartis AG Stock (NVS) Moved Down by 3.16% on Mar 11: Drivers Behind the Movement

• Novartis stock declined due to trading ex-dividend for $4.773 per share. • Q4 2025 earnings beat expectations, but revenue missed analyst targets. • 2026 operating profit forecast projects a low single-digit percentage decline.

TradingKeyWed, Mar 11
• Novartis stock declined due to trading ex-dividend for $4.773 per share.
• Q4 2025 earnings beat expectations, but revenue missed analyst targets.
• 2026 operating profit forecast projects a low single-digit percentage decline.
KeyAI